Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum

被引:33
|
作者
Subehan
Usia, Tepy
Kadota, Shigetoshi
Tezuka, Yasuhiro [1 ]
机构
[1] Toyama Univ, Inst Nat Med, Toyama 9300194, Japan
[2] Toyama Univ, 21st Century COE Program, Toyama 9300194, Japan
关键词
Piper nigrum; alkamides; cytochrome P450 2D6; CYP2D6; mechanism-based inhibition; drug-herb interaction;
D O I
10.1055/s-2006-931558
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Nineteen alkamides isolated from Piper nigrum L. were tested for their mechanism-based inhibition on human liver microsomal dextromethorphan O-demethylation activity, a prototype marker for cytochrome P450 2D6 (CYP2D6). All compounds increased their inhibitory activity with increasing preincubation time. Among them, 15 and 17 showed more than 50% decrease of the CYP2D6 residual activity after 20 min preincubation. Further investigations on 15 and 17 showed that the characteristic time and concentration-dependent inhibition, which required a catalytic step with NADPH, was not protected by nucleophiles, and was decreased by the presence of a competitive inhibitor. The kinetic. parameters for inactivation (k(inact) and k(I)) were 0.028 min(-1) and 0.23 mu M for 15 and 0.064 min(-1) and 0.71 mu M for 17, respectively, which were stronger than the known mechanism-based inhibitor, paroxetine (a positive control). Thus, 15 and 17 are potent mechanism-based inhibitors of CYP2D6.
引用
收藏
页码:527 / 532
页数:6
相关论文
共 50 条
  • [1] Alkamides from Piper nigrum L. and their inhibitory activity against human liver microsomal cytochrome P450 2D6 (CYP2D6)
    Subehan
    Usia, Tepy
    Kadota, Shigetoshi
    Tezuka, Yasuhiro
    NATURAL PRODUCT COMMUNICATIONS, 2006, 1 (01) : 1 - 7
  • [2] INHIBITION OF HUMAN CYTOCHROME P450 2D6 (CYP2D6) BY METHADONE
    WU, D
    OTTON, SV
    SPROULE, BA
    BUSTO, U
    INABA, T
    KALOW, W
    SELLERS, EM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 35 (01) : 30 - 34
  • [3] Mechanism-Based Inhibition of Human Cytochrome P450 2D6 by Schering 66712
    Mocny, Catherine S.
    Arthur, Evan J.
    Butler, Brendan F.
    Diffenderfer, Laura E.
    Palamanda, Jairam R.
    Guengerich, F. Peter
    Nomeir, Amin A.
    Furge, Laura Lowe
    FASEB JOURNAL, 2010, 24
  • [4] Functional Characterization of Cytochrome P450 2D6 (CYP2D6) Allelic Variant CYP2D6*10
    Dong, A. N.
    Ong, C. E.
    Pan, Y.
    Palanisamy, U. D.
    Ismail, R.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 49 - 49
  • [5] GENETIC POLYMORPHISM IN CYTOCHROME P450 2D6 (CYP2D6): POPULATION DISTRIBUTION OF CYP2D6 ACTIVITY
    Neafsey, Patricia
    Ginsberg, Gary
    Hattis, Dale
    Sonawane, Babasaheb
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2009, 12 (5-6): : 334 - 361
  • [6] Mechanism-based inactivation of cytochrome P450 2D6 by Notopterol
    Fu, Yao
    Tian, Xiaoxiao
    Han, Lingling
    Li, Yilin
    Peng, Ying
    Zheng, Jiang
    CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 322
  • [7] Methadone is not a mechanism-based inhibitor of cytochrome P450 2D6
    Heydari, A
    Rostami-Hodjegan, A
    Rowland-Yeo, K
    Lennard, MS
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (05) : 687 - 687
  • [8] Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine
    Liu, Yuyang
    Cui, Tiantian
    Peng, Ying
    Ji, Mingshan
    Zheng, Jiang
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2019, 33 (02)
  • [9] Cytochrome p450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus
    Usia, T
    Watabe, T
    Kadota, S
    Tezuka, Y
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (06) : 1021 - 1024
  • [10] Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping
    Streetman, DS
    Ellis, RE
    Nafziger, AN
    Leeder, JS
    Gaedigk, A
    Gotschall, R
    Kearns, GL
    Bertino, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (05) : 535 - 541